Research Keyword: invasive fungal disease

Persister cells in human fungal pathogens

mycolabadmin

Some fungal infections fail to respond to antifungal drugs even when the fungus should be susceptible to treatment. This happens because certain fungal cells can enter a dormant ‘sleep-like’ state that helps them survive drug exposure. These dormant cells, called persisters, are able to hide from medications by reducing their metabolism and enhancing their protective defenses. Understanding how these persister cells form and survive could lead to better treatments for serious fungal infections.

Read More »

Antifungal stewardship in the UK: where are we now?

mycolabadmin

This paper examines how well the UK is currently managing antifungal stewardship—the appropriate use of antifungal medications to treat serious fungal infections while preventing resistance. Experts found that since 2017, progress has been limited due to lack of funding and staff expertise, difficulties accessing timely fungal diagnostic tests, and disruptions from the COVID-19 pandemic. The panel recommends creating regional mycology networks and diagnostic centres, establishing national standards for antifungal practices, and improving education about fungal infections to better prepare the UK for rising fungal disease threats.

Read More »

The Prognostic Value of (1→3)-β-D-Glucan in COVID-19 Patients with and Without Secondary Fungal Disease

mycolabadmin

During COVID-19, patients in intensive care sometimes develop dangerous fungal infections. Doctors use a blood test to measure a fungal marker called BDG to help diagnose these infections. This study found that even without confirmed fungal infection, high BDG levels predicted who would not survive, but giving antifungal medications improved survival even without proven infection.

Read More »

Invasive Fungal Disease is Rare in Multiple Myeloma Patients Treated with BCMA CAR-T Therapy

mycolabadmin

Researchers studied patients with multiple myeloma who received a new type of cancer treatment called BCMA CAR-T cell therapy. While this powerful therapy can sometimes increase infection risk, the study found that serious fungal infections occurred in only a small percentage of patients (1.7%). However, when these fungal infections did occur, they were often severe and potentially life-threatening, particularly in patients who experienced significant side effects from the therapy.

Read More »

Gastrointestinal and Intra-Abdominal Mucormycosis in Non-Haematological Patients—A Comprehensive Review

mycolabadmin

This review examines a serious but rare fungal infection called mucormycosis that affects the stomach and intestines. The infection most commonly occurs in patients with diabetes, those who have received organ transplants, or those in intensive care units. Diagnosis can be difficult because symptoms are non-specific, but prompt treatment with antifungal medications and surgery when possible significantly improves survival rates. Early recognition and rapid diagnosis are critical for patients to have the best outcomes.

Read More »

Pan-Indian Clinical Registry of Invasive Fungal Infections Among Patients in the Intensive Care Unit: Protocol for a Multicentric Prospective Study

mycolabadmin

Fungal infections are a serious hidden threat in hospital intensive care units, particularly for patients with weakened immune systems. This study establishes India’s first comprehensive database system to track fungal infections across 8 major medical centers nationwide. By collecting detailed information about these infections and how they respond to treatments, the research aims to help doctors diagnose and treat fungal infections faster and more effectively. The findings will guide better clinical practices and public health policies to combat these often-neglected but deadly infections.

Read More »

Advancing Patient Advocacy in Mycology: Cultivating Collaboration in Education, Research, and Policy

mycolabadmin

Fungal infections are a serious public health problem, but unlike cancer and AIDS, they lack strong patient advocacy movements to raise awareness and secure funding. This paper argues that patients with fungal diseases have important insights about their care needs that could help improve policies and research if their voices were heard. The authors propose establishing unified advocacy organizations, like the MyCARE Foundation, to bring patients, doctors, and policymakers together to better address this neglected health challenge.

Read More »
Scroll to Top